Ablynx NV (ABLX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH6397D
- Pages: 77
- November 2018
- Total Views:1288
- Region : Europe
- GlobalData
- Equity Research Report
Details
Summary
Ablynx NV (Ablynx) is a biopharmaceutical company that focuses on developing Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional properties of naturally-occurring heavy chain only antibodies. It has advantages of conventional antibodies along with the key features of small molecule drugs. Ablynx develops Nanobodies to treat serious human diseases including acquired thrombotic thrombocytopenic purpura (aTTp), psoriasis, bone disorders, cancer and pulmonary diseases. The company has ongoing research collaborations and significant partnerships with key pharmaceutical companies including Merck, Boehringer Ingelheim and Novartis. Ablynx is headquartered in Ghent, Belgium.
Ablynx NV (ABLX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14
Partnerships 15
Ablynx Exercises Option for Licensing Agreement with Vectura 15
Ablynx Enters into Research Agreement with Genzyme 16
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17
Taiwan Liposome and Ablynx Enter into Research Agreement 18
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19
Licensing Agreements 20
Sanofi Signs Licensing Agreement with Ablynx 20
Novo Nordisk Enters into Licensing Agreement with Ablynx 21
Taisho Pharma Enters into Licensing Agreement with Ablynx 22
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23
Merck Expands Licensing Agreement with Ablynx 24
Ablynx Enters Into Licensing Agreement With Eddingpharm 26
Equity Offering 28
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33
Ablynx Amends Private Placement of Shares 34
Ablynx Raises USD1.05 Million Through Exercise of Warrants 36
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39
Ablynx Raises USD82.6 Million in Private Placement of Shares 40
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42
Ablynx Raises USD1.4 Million upon Exercise of Warrants 43
Ablynx Raises USD57 Million in Private Placement of Shares 44
Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46
Ablynx Completes Private Placement Of Shares For USD 41 Million 47
Debt Offering 49
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49
Acquisition 50
Sanofi Acquires Ablynx for USD4.85 Billion 50
Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54
Ablynx NV-Key Competitors 55
Ablynx NV-Key Employees 56
Ablynx NV-Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Recent Developments 58
Financial Announcements 58
Feb 22, 2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS 58
Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 61
Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 63
May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 66
Feb 23, 2017: Ablynx Announces 2016 Full Year Results 68
Corporate Communications 69
Feb 07, 2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors 69
Jan 24, 2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer 70
Jan 08, 2018: Ablynx Announces Board Changes 71
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 72
Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 73
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 74
Clinical Trials 75
Jan 11, 2017: Ablynx Initiates Phase IIb Respire Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
List Of Figure
List of Figures
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14
Ablynx Exercises Option for Licensing Agreement with Vectura 15
Ablynx Enters into Research Agreement with Genzyme 16
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17
Taiwan Liposome and Ablynx Enter into Research Agreement 18
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19
Sanofi Signs Licensing Agreement with Ablynx 20
Novo Nordisk Enters into Licensing Agreement with Ablynx 21
Taisho Pharma Enters into Licensing Agreement with Ablynx 22
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23
Merck Expands Licensing Agreement with Ablynx 24
Ablynx Enters Into Licensing Agreement With Eddingpharm 26
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33
Ablynx Amends Private Placement of Shares 34
Ablynx Raises USD1.05 Million Through Exercise of Warrants 36
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39
Ablynx Raises USD82.6 Million in Private Placement of Shares 40
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42
Ablynx Raises USD1.4 Million upon Exercise of Warrants 43
Ablynx Raises USD57 Million in Private Placement of Shares 44
Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46
Ablynx Completes Private Placement Of Shares For USD 41 Million 47
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49
Sanofi Acquires Ablynx for USD4.85 Billion 50
Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54
Ablynx NV, Key Competitors 55
Ablynx NV, Key Employees 56
Ablynx NV, Subsidiaries 57
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Ablynx NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Ablynx NV (Ablynx) is a biopharmaceutical company that focuses on developing Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional properties of naturally-occurring heavy chain only antibodies. It has advantages of conventional antibodies along with the key features of small molecule drugs. Ablynx develops Nanobodies to treat serious human diseases including acquired thrombotic thrombocytopenic purpura (aTTp), psoriasis, bone disorders, cancer and pulmonary diseases. The company has ongoing research collaborations and significant partnerships with key pharmaceutical companies including Merck, Boehringer Ingelheim and Novartis. Ablynx is headquartered in Ghent, Belgium.
Ablynx NV (ABLX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Ablynx NV, Pharmaceuticals & Healthcare, Deal Details 14
Private Equity 14
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14
Partnerships 15
Ablynx Exercises Option for Licensing Agreement with Vectura 15
Ablynx Enters into Research Agreement with Genzyme 16
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17
Taiwan Liposome and Ablynx Enter into Research Agreement 18
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19
Licensing Agreements 20
Sanofi Signs Licensing Agreement with Ablynx 20
Novo Nordisk Enters into Licensing Agreement with Ablynx 21
Taisho Pharma Enters into Licensing Agreement with Ablynx 22
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23
Merck Expands Licensing Agreement with Ablynx 24
Ablynx Enters Into Licensing Agreement With Eddingpharm 26
Equity Offering 28
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33
Ablynx Amends Private Placement of Shares 34
Ablynx Raises USD1.05 Million Through Exercise of Warrants 36
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39
Ablynx Raises USD82.6 Million in Private Placement of Shares 40
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42
Ablynx Raises USD1.4 Million upon Exercise of Warrants 43
Ablynx Raises USD57 Million in Private Placement of Shares 44
Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46
Ablynx Completes Private Placement Of Shares For USD 41 Million 47
Debt Offering 49
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49
Acquisition 50
Sanofi Acquires Ablynx for USD4.85 Billion 50
Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54
Ablynx NV-Key Competitors 55
Ablynx NV-Key Employees 56
Ablynx NV-Locations And Subsidiaries 57
Head Office 57
Other Locations & Subsidiaries 57
Recent Developments 58
Financial Announcements 58
Feb 22, 2018: ABLYNX ANNOUNCES 2017 FULL YEAR RESULTS 58
Nov 16, 2017: Ablynx Announces Results For The First Nine Months Of 2017 And A Year-To-Date Business Update 61
Aug 24, 2017: Ablynx Announces 2017 Half Year Results and Year-to-date Business Update 63
May 11, 2017: Ablynx Reports Financial Results for the First Three Months Of 2017 and a Year-To-Date Business Update 66
Feb 23, 2017: Ablynx Announces 2016 Full Year Results 68
Corporate Communications 69
Feb 07, 2018: Ablynx Announces Resignation of Dr Bo Jesper Hansen From the Board of Directors 69
Jan 24, 2018: Ablynx Names Dr Robert Friesen as Chief Scientific Officer 70
Jan 08, 2018: Ablynx Announces Board Changes 71
Jul 17, 2017: Ablynx Proposes Appointment of Mrs Hilde Windels as a New Independent Director 72
Jun 13, 2017: Ablynx Appoints Markus Ewert As Chief Business Officer 73
Mar 07, 2017: Merck reports positive data from Phase Ib trial of M1095 in psoriasis patients 74
Clinical Trials 75
Jan 11, 2017: Ablynx Initiates Phase IIb Respire Study of its Inhaled Anti-RSV Nanobody, Alx-0171, For Treatment of RSV Infections In Hospitalised Infants 75
Appendix 77
Methodology 77
About GlobalData 77
Contact Us 77
Disclaimer 77
List Of Figure
List of Figures
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
List Of Table
List of Tables
Ablynx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Ablynx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Ablynx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Ablynx NV, Deals By Therapy Area, 2012 to YTD 2018 10
Ablynx NV, Medical Devices Deals, 2012 to YTD 2018 11
Ablynx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BVF Partners Acquires Additional 1.74% Stake In Ablynx From Sofinnova 14
Ablynx Exercises Option for Licensing Agreement with Vectura 15
Ablynx Enters into Research Agreement with Genzyme 16
Ablynx Extends Agreement with Merck to Develop Therapeutic Nanobody Candidates 17
Taiwan Liposome and Ablynx Enter into Research Agreement 18
Ablynx Enters Into Agreement With Merck To Develop Therapeutic Nanobody Candidates 19
Sanofi Signs Licensing Agreement with Ablynx 20
Novo Nordisk Enters into Licensing Agreement with Ablynx 21
Taisho Pharma Enters into Licensing Agreement with Ablynx 22
Ablynx Enters into Licensing Agreement with Eddingpharm for Anti-TNFa Nanobody 23
Merck Expands Licensing Agreement with Ablynx 24
Ablynx Enters Into Licensing Agreement With Eddingpharm 26
Ablynx Raises USD2.3 Million in Private Placement of Shares up on Exercise of Warrants 28
Ablynx Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 29
Ablynx Raises USD2 Million in Private Placement of Shares up on Exercise of Warrants 30
Ablynx Completes Underwriters Exercise of Over-Allotment Option of Public Offering of ADS for USD230 Million 31
Ablynx Raises USD1.1 Million in Private Placement of Shares upon Exercise of Warrants 33
Ablynx Amends Private Placement of Shares 34
Ablynx Raises USD1.05 Million Through Exercise of Warrants 36
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 37
Ablynx Raises USD0.1 Million in Private Placement of Shares upon Exercise of Warrants 38
Ablynx Raises USD0.4 Million in Private Placement of Shares upon Exercise of Warrants 39
Ablynx Raises USD82.6 Million in Private Placement of Shares 40
Ablynx Raises USD0.05 Million in Private Placement of Shares upon Exercise of Warrants 42
Ablynx Raises USD1.4 Million upon Exercise of Warrants 43
Ablynx Raises USD57 Million in Private Placement of Shares 44
Ablynx Completes Private Placement Of Shares For USD 1.2 Million Upon Exercise Of Warrants 46
Ablynx Completes Private Placement Of Shares For USD 41 Million 47
Ablynx Raises USD112 Million in Private Placement of 3.25% Bonds Due 2020 49
Sanofi Acquires Ablynx for USD4.85 Billion 50
Sofinnova Divests Its Stake In Ablynx For USD 29.4 Million 52
Gimv And Biotech Fonds Vlaanderen Sell Remaining Stake In Ablynx 53
Gimv And Biotech Fonds Vlaanderen Sell Stake In Ablynx 54
Ablynx NV, Key Competitors 55
Ablynx NV, Key Employees 56
Ablynx NV, Subsidiaries 57
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Ablynx NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
: +91 9015378249
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020